Podcast9

CONFLITO DE INTERESSES DECLARADO POR TODOS OS PROFISSIONAIS DE SAÚDE CITADOS ACIMA

De acordo com a resolução 1931/2009 do Conselho Federal de Medicina e com a RDC 96/2008 da ANVISA, declaro que recebi honorários da Gilead para esse evento.

Referências:

Bula professional TRODELVY; Zhao W, Kuai X, Zhou X, et al. Trop2 is a potential biomarker for the promotion of EMT in human breast cancer. Oncol Rep. 2018; 40(2):759-766; Guerra E, Trerotola M, Alberti S. Targeting Trop-2 as a Cancer Driver. J Clin Oncol. 2023; 41(29):4688-4692; BardiaA, Tolaney SM, Punie K, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol. 2021; 32(9):1148-1156; RugoHS, Bardia A, Marmé F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023 :S0140-6736(23)01245-X. st cancer [Oral Presentation 1003]. Presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2023; Chicago, IL